TScan Therapeutics Inc TCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.97
- Day Range
- $4.90–5.08
- 52-Week Range
- $2.43–9.69
- Bid/Ask
- $4.84 / $5.34
- Market Cap
- $266.99 Mil
- Volume/Avg
- 170,490 / 347,185
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 188
- Website
- https://www.tscan.com
Comparables
Valuation
|
Metric
|
TCRX
|
KYTX
|
GTHX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.05 | 0.68 | 15.32 |
Price/Sales | 41.24 | — | 6.40 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TCRX
|
KYTX
|
GTHX
|
|---|---|---|---|
Quick Ratio | 7.72 | 14.75 | 1.97 |
Current Ratio | 7.77 | 14.86 | 2.48 |
Interest Coverage | −29.80 | −558.59 | −3.99 |
Quick Ratio
TCRX
KYTX
GTHX
Profitability
|
Metric
|
TCRX
|
KYTX
|
GTHX
|
|---|---|---|---|
Return on Assets (Normalized) | −32.50% | −37.69% | −29.58% |
Return on Equity (Normalized) | −54.73% | −76.90% | −94.76% |
Return on Invested Capital (Normalized) | −39.01% | −77.97% | −33.14% |
Return on Assets
TCRX
KYTX
GTHX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tjylxnjjf | Hjy | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ppdfxqlx | Cmsbkvf | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bbvwpplx | Nzwdpr | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yypwkqg | Lpffmc | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Wqzgqthv | Pgkr | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vmjkfxhkx | Tvfw | $28.1 Bil | |||
| Moderna Inc
MRNA
| Qfytppkmz | Wfxm | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Mjzbpdmxd | Gddf | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Chrxdtqw | Dpsvxy | $13.4 Bil | |||
| Incyte Corp
INCY
| Xhdmktr | Bykfxj | $12.7 Bil |
United States